Novo Nordisk's Quarter Cuts Both Ways: A 27% Adjusted Surge, a 9% Reported Slide, and a CFO Handover

Novo Nordisk closed Wednesday's session 4.8% higher after quarterly figures landed ahead of expectations, with Reuters attributing part of the advance to an upgraded full-year outlook. The headline gain, however, sits on top of a set of numbers that tell two different stories depending on which line of the income statement an investor chooses to read first.

Two profit lines, one reporting period

At constant exchange rates, the Danish drugmaker's adjusted operating profit climbed 27% to DKK 31.72bn in the third quarter of 2026. On the same currency basis, the reported operating result fell 9%. Neither figure contradicts the other — they simply describe different levels of the same result.

The gap comes down to impairment charges. Non-cash writedowns of DKK 8.7bn were booked in the reported result, and the adjusted metric strips that effect out. Read the adjusted number alone and a material piece of the quarterly balance sheet disappears from view; read only the reported decline and the underlying operating trend is left equally incomplete.

Revenue on an adjusted basis reached DKK 79.2bn, up 4% at constant currencies — meaning profit growth outpaced the top line by a wide margin rather than riding on it.

The Wegovy pill delivers the upside

The clearest business driver was the Wegovy pill, which generated DKK 5.39bn in sales during the quarter, beating the DKK 4.62bn analyst consensus reported by Reuters. Novo Nordisk pointed to continued volume growth in GLP-1 products, particularly in obesity, and Reuters said the stronger-than-expected pill business helped support the guidance raise.

That lift now sets adjusted sales and adjusted operating profit growth for 2026 at a range of -2% to +2% in local currencies. The forecast still leaves room for a decline as well as an increase — a point worth holding onto, since the quarter's brisk adjusted profit gain should not be mistaken for an equivalent full-year growth expectation.

Jefferies stays on the sidelines

Jefferies reiterated its Hold rating and DKK 275 price target on Wednesday. Consensus estimates sat roughly 3 percentage points below the midpoint of the company's new guidance, the broker noted, leaving room for upward revisions to forecasts. No upgrade accompanied the call, and Jefferies stressed that an operational beat on its own does not justify a Buy.

That leaves the stock's reaction running ahead of the analyst response, and the distinction matters: a stronger business trajectory and a re-rating of the equity are not the same thing.

A new finance chief alongside the numbers

Novo Nordisk also used the release to announce a leadership change. Luigi La Corte, currently CFO of Galderma, has been appointed Executive Vice President and Chief Financial Officer. Karsten Munk Knudsen will leave the company at the end of the year after 27 years.

The handover is a separate corporate development rather than a documented driver of Wednesday's share price move. What remains central to the investment case is the combination of a better-than-expected quarter, the possibility of higher consensus estimates, and a full-year outlook that still permits contraction — with impairments weighing on the reported bottom line and Jefferies making plain that a single strong quarter is not yet a reason to buy.